IRB #

STUDY00017603

Title

Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma

Principal Investigator

Charles Lopez

Study Purpose

To determine effectiveness of ADI-PEG 20 in combination with FOLFOX in hepatocellular carcinoma (HCC)

Medical Condition(s)

"Hepatocellular", "ADI-PEG 20", "FOLFOX"

Eligibility Criteria

Advanced, histologically proven HCC
No prior systemic therapy within the last 2 weeks
Age ≥ 18 years

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

2 years

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Polaris Pharmaceuticals Inc

Recruitment End

09/25/2032

Compensation Provided

No


Go Back